​

Syndax Pharmaceuticals (SNDX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

SNDX Stock Forecast

Syndax Pharmaceuticals (SNDX) stock forecast, based on 22 Wall Street analysts, predicts a 12-month average price target of $39.33, with a high of $45.00 and a low of $35.00. This represents a 67.36% increase from the last price of $23.50.

$10 $17 $24 $31 $38 $45 High: $45 Avg: $39.33 Low: $35 Last Closed Price: $23.5

SNDX Stock Rating

Syndax Pharmaceuticals stock's rating consensus is Buy, based on 22 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 20 Buy (90.91%), 2 Hold (9.09%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 22 0 2 20 Strong Sell Sell Hold Buy Strong Buy

SNDX Price Target Upside V Benchmarks

TypeNameUpside
StockSyndax Pharmaceuticals67.36%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts117
Avg Price Target$45.00$45.00$33.86
Last Closing Price$23.50$23.50$23.50
Upside/Downside91.49%91.49%44.09%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26210---12
Feb, 26212---14
Jan, 26212---14
Dec, 25212---14
Nov, 25311---14
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 27, 2026Stephen WilleyStifel Nicolaus$45.00$21.71107.28%91.49%
Nov 24, 2025Barclays$35.00$17.44100.69%48.94%
Nov 04, 2025UBS$38.00$13.76176.16%61.70%
Nov 04, 2025Peter LawsonBarclays$22.00$13.7659.88%-6.38%
Sep 10, 2025Stifel Nicolaus$44.00$15.73179.72%87.23%
Jul 15, 2025David DaiUBS$35.00$9.80257.14%48.94%
Jul 10, 2025Corinne JohnsonGoldman Sachs$18.00$9.8283.30%-23.40%
Nov 13, 2024George FarmerScotiabank$18.00$20.04-10.18%-23.40%
Oct 24, 2024David DaiUBS$37.00$18.5499.57%57.45%
Aug 15, 2024Yigal NochomovitzCitigroup$34.00$20.0969.24%44.68%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Nov 24, 2025BarclaysOverweightOverweighthold
Nov 04, 2025UBSBuyBuyhold
Nov 04, 2025BarclaysOverweightOverweighthold
Aug 05, 2025CitigroupBuyBuyhold
Aug 05, 2025BTIGBuyBuyhold
Jul 15, 2025UBSBuyBuyhold
Jul 10, 2025Goldman SachsBuyBuyinitialise
May 06, 2025ScotiabankSector PerformSector Performhold
Nov 13, 2024ScotiabankSector PerformSector Performhold
Oct 24, 2024UBSBuyinitialise

Financial Forecast

EPS Forecast

$-9 $-7 $-5 $-3 $-1 $1 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.48$-2.46$-2.98$-3.73----
Avg Forecast$-2.04$-2.53$-2.95$-3.48$-3.85$-2.65$-1.64$-0.32
High Forecast$-0.73$-0.41$-2.88$-2.85$-3.24$-0.74$-0.96$-0.13
Low Forecast$-4.60$-8.09$-3.13$-3.67$-4.50$-3.45$-2.43$-0.74
Surprise %-123.53%-2.77%1.02%7.18%----

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$139.71M--$23.68M$172.35M---
Avg Forecast$19.15M$375.00K-$48.72M$98.48M$234.54M$347.18M$537.00M
High Forecast$37.59M$1.01M-$134.94M$132.74M$234.55M$688.50M$1.06B
Low Forecast$9.68M$132.85K-$23.22M$59.51M$234.52M$184.39M$285.21M
Surprise %629.55%---51.40%75.01%---

Net Income Forecast

$-600M $-470M $-340M $-210M $-80M $50M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$24.93M$-149.34M$-209.36M$-318.76M$-285.42M---
Avg Forecast$-143.68M$-178.14M$-209.36M$-229.54M$-272.53M$-240.79M$-124.49M$-22.82M
High Forecast$-51.34M$-28.60M$-202.38M$-200.80M$-228.32M$-52.08M$-67.65M$-8.91M
Low Forecast$-323.55M$-569.42M$-220.52M$-258.27M$-316.74M$-242.60M$-171.23M$-51.99M
Surprise %-117.35%-16.17%-38.87%4.73%---

SNDX Forecast FAQ

Is Syndax Pharmaceuticals stock a buy?

Syndax Pharmaceuticals stock has a consensus rating of Buy, based on 22 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 20 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Syndax Pharmaceuticals is a favorable investment for most analysts.

What is Syndax Pharmaceuticals's price target?

Syndax Pharmaceuticals's price target, set by 22 Wall Street analysts, averages $39.33 over the next 12 months. The price target range spans from $35 at the low end to $45 at the high end, suggesting a potential 67.36% change from the previous closing price of $23.5.

How does Syndax Pharmaceuticals stock forecast compare to its benchmarks?

Syndax Pharmaceuticals's stock forecast shows a 67.36% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Syndax Pharmaceuticals over the past three months?

  • March 2026: 16.67% Strong Buy, 83.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 14.29% Strong Buy, 85.71% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 14.29% Strong Buy, 85.71% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Syndax Pharmaceuticals’s EPS forecast?

Syndax Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $-2.65, marking a 0% decrease from the reported $0 in 2025. Estimates for the following years are $-1.64 in 2027, and $-0.32 in 2028.

What is Syndax Pharmaceuticals’s revenue forecast?

Syndax Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $234.54M, reflecting a 36.08% increase from the reported $172.35M in 2025. The forecast for 2027 is $347.18M, and $537M for 2028.

What is Syndax Pharmaceuticals’s net income forecast?

Syndax Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $-241M, representing a -15.64% decrease from the reported $-285M in 2025. Projections indicate $-124M in 2027, and $-22.823M in 2028.